Studies examine rheumatoid arthritis patients' prognosis

April 20, 2017

What's the long-term outlook for today's patients with early rheumatoid arthritis? A new study in Arthritis & Rheumatology that looks at patients' mortality, disease activity, and physical function over the course of 20 years reveals the importance of early treatment. Another study in the journal notes that deaths from arthritis are declining.

Investigators led by Suzanne Verstappen, PhD, of The University of Manchester in the UK, analyzed information on 602 rheumatoid arthritis patients from the Norfolk Arthritis Register who were recruited from 1990 to 1994. The team collected demographic variables and assessed disease activity (swollen/tender joint counts), disability, and mortality at various time points over 20 years.

Overall, patients had relatively low levels of disease activity from year one onwards, but disability rose to above baseline levels after seven years. This disability was moderate, however, indicating that patients experienced relatively good long-term outcomes, particularly compared with patients from earlier decades.

Patients who received treatment within six months after symptom onset had similar levels of disability over the subsequent 20 years as patients who were judged by clinicians to not require treatment. A total of 265 patients (44 percent) died, and, although not significant, there was a trend indicating that patients who received treatment within the first six months had a lower risk of death than those who did not receive treatment, after controlling for disease severity.

"This research emphasizes the importance of early treatment and the long-term benefits of early treatment," said Dr. Verstappen. "In the early 1990s, when this study started, only 30 percent of patients received early treatment, but this number has increased significantly in the last decade. It's expected that in the next 10 years, newly diagnosed patients will have a better future with respect to functional ability, less severe disease activity, and improved quality of life."

Another analysis in the journal notes that deaths attributable to rheumatoid arthritis have declined in recent years. After examining information from 31 countries, investigators found that there are substantial between-country disparities in rheumatoid arthritis mortality, but the disparities have decreased over time.

According to data from the World Health Organization, rheumatoid arthritis was registered as the underlying cause of death in 8428 cases in 2011 (0.09% of all-cause deaths), a considerable drop compared with the 9281 cases (0.12% of all-cause deaths) in 1987. The age-standardized mortality rate of rheumatoid arthritis declined by 3.0% annually from 1987 to 2011.

Population aging combined with fewer deaths from rheumatoid arthritis may lead to an increased economic burden of the disease.

"Although increased survival with rheumatoid arthritis is great news, it might lead to a greater share of our aging population having the disease and in need of health services. This needs to be accounted for in health care planning", said lead author Aliasghar Kiadaliri, PhD, of Lund University in Sweden.
-end-
Additional Information

Full Citation: "The 20 year outcome and association between early treatment and mortality and disability in an inception cohort of patients with rheumatoid arthritis: results from the Norfolk Arthritis Register." James M. Gwinnutt, Deborah P.M. Symmons, Alexander J. MacGregor, Jacqueline R. Chipping, Tarnya Marshall, Mark Lunt, and Suzanne M.M. Verstappen. Arthritis & Rheumatology; Published Online: April 20, 2017 (DOI: 10.1002/art.40090).

Link to Study: http://doi.wiley.com/10.1002/art.40090

Full Citation: "Rheumatoid arthritis as underlying cause of death in 31 countries, 1987-2011: trend analysis of WHO mortality database." Aliasghar A. Kiadaliri, David T. Felson, Tuhina Neogi, and Martin Englund. Arthritis & Rheumatology; Published Online: April 20, 2017 (DOI: 10.1002/art.40091).

Link to Study: http://doi.wiley.com/10.1002/art.40091

Author Contacts: For Dr. Verstappen: Michael Addelman, of The University of Manchester's Media Relations Office, at michael.addelman@manchester.ac.uk or +44 (0) 161 275 2111.

For Dr. Kiadaliri: aliasghar.ahmad_kiadaliri@med.lu.se

About the Journal

Arthritis & Rheumatology is an official journal of the American College of Rheumatology (ACR) and covers all aspects of inflammatory disease. The American College of Rheumatology (http://www.rheumatology.org) is the professional organization whose members share a dedication to healing, preventing disability, and curing the more than 100 types of arthritis and related disabling and sometimes fatal disorders of the joints, muscles, and bones. Members include practicing physicians, research scientists, nurses, physical and occupational therapists, psychologists, and social workers. The journal is published by Wiley on behalf of the ACR. For more information, please visit http://wileyonlinelibrary.com/journal/art.

About Wiley

Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, learned societies, businesses, governments and individuals increase the academic and professional impact of their work. For more than 200 years, we have delivered consistent performance to our stakeholders. The company's website can be accessed at http://www.wiley.com.

Wiley

Related Rheumatoid Arthritis Articles from Brightsurf:

Reducing dementia in patients with rheumatoid arthritis
The incidence of dementia in patients with rheumatoid arthritis is lower in patients receiving biologic or targeted synthetic disease modifying antirheumatic drugs (DMARDs) than in patients who receive conventional synthetic DMARDs, according to a new study.

Is rheumatoid arthritis two different diseases?
While disease activity improves over time for most rheumatoid arthritis (RA) patients, long-term outcomes only improve in RA patients with autoantibodies, according to a new study published this week in PLOS Medicine by Xanthe Matthijssen of Leiden University Medical Center, Netherlands, and colleagues.

Does the Mediterranean diet protect against rheumatoid arthritis?
Previous research has demonstrated a variety of health benefits associated with the Mediterranean diet, which is rich in olive oil, cereals, fruit and vegetables, fish, and a moderate amount of dairy, meat, and wine.

Reducing corticosteroid use in rheumatoid arthritis
Is the long-term use of glucocorticoids essential in people with chronic inflammatory diseases such as rheumatoid arthritis, or can early discontinuation prevent characteristic side effects?

Rheumatoid arthritis patients under treatment with methotrexate
Patients with rheumatoid arthritis (RA) often suffer from what is referred to as interstitial lung disease (ILD).

Rheumatoid arthritis -- can its onset be delayed or prevented?
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that leads to significant health issues as well as high treatment costs.

Disease burden in osteoarthritis is similar to rheumatoid arthritis
Osteoarthritis (OA) has traditionally been viewed as a highly prevalent but milder condition when compared with rheumatoid arthritis (RA), and some may believe that it is part of a normal aging process requiring acceptance, not treatment.

Prospect of a new treatment for rheumatoid arthritis
An international research group led by Charité -- Universitätsmedizin Berlin has completed testing a new drug to treat rheumatoid arthritis.

Can rare lymphocytes combat rheumatoid arthritis?
Immunologists at Friedrich-Alexander-Universität Erlangen-Nürnberg have demonstrated that ILC2, a group of rare lymphoid cells, play a key role in the development of inflammatory arthritis.

Rheumatoid arthritis meets precision medicine
Scientists are bringing precision medicine to rheumatoid arthritis for the first time by using genetic profiling of joint tissue to see which drugs will work for which patients, reports a new multi-site study.

Read More: Rheumatoid Arthritis News and Rheumatoid Arthritis Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.